Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 ( OX2R ) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

a week ago

BOSTON and LONDON, Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc ( Nasdaq: CNTA ) , a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced positive interim data from an ongoing Phase 1 trial ...

Ticker	Sentiment	Impact
CNTA	Neutral	6 %